October 25, 2022 – ICR Study Raises Possibility of Predicting Drug Resistance in Advance

A new study led by scientists at the Institute of Cancer Research, London (ICR) and The Royal Marsden NHS Foundation Trust has shown how stomach cancers can evade the effects of a new class of drugs, raising the possibility of being able to predict drug resistance in advance.

The researchers found that stomach cancers could develop resistance to ATR inhibitors by switching off the activity of two genes, meaning genetic tests could be used in the future to select patients whose cancers are most likely to respond to this class of drugs.